HORMEL FOODS CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HORMEL FOODS CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Oct 29, 2017 | $2.49B | Dec 20, 2017 |
| FY2017 | Jul 30, 2017 | $2.21B | Dec 20, 2017 |
| FY2017 | Apr 30, 2017 | $2.19B | Dec 20, 2017 |
| FY2017 | Jan 29, 2017 | $2.28B | Dec 20, 2017 |
| FY2016 | Oct 30, 2016 | $2.63B | Dec 21, 2016 |
| FY2016 | Jul 24, 2016 | $2.30B | Dec 21, 2016 |
| FY2016 | Apr 24, 2016 | $2.30B | Dec 21, 2016 |
| FY2016 | Jan 24, 2016 | $2.29B | Dec 21, 2016 |
| FY2015 | Oct 25, 2015 | $2.40B | Dec 16, 2015 |
| FY2015 | Jul 26, 2015 | $2.19B | Dec 16, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $1.89B | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $2.02B | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $2.00B | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $2.16B | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $1.93B | Dec 6, 2023 |
| FY2020 | Oct 25, 2020 | $457.77M | Dec 4, 2020 |
| FY2020 | Jul 26, 2020 | $422.43M | Dec 4, 2020 |
| FY2020 | Apr 26, 2020 | $477.35M | Dec 4, 2020 |
| FY2020 | Jan 26, 2020 | $468.42M | Dec 4, 2020 |
| FY2020 | Oct 27, 2019 | $493.72M | Dec 4, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $478.20M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $805.04M | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $793.57M | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $999.99M | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $908.84M | Dec 6, 2023 |
| FY2020 | Oct 25, 2020 | $234.36M | Dec 4, 2020 |
| FY2020 | Jul 26, 2020 | $203.12M | Dec 4, 2020 |
| FY2020 | Apr 26, 2020 | $227.73M | Dec 4, 2020 |
| FY2020 | Jan 26, 2020 | $242.87M | Dec 4, 2020 |
| FY2020 | Oct 27, 2019 | $255.50M | Dec 4, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $718.60M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $1.07B | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $1.07B | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $1.31B | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $1.12B | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $1.10B | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $1.20B | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $1.18B | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $1.28B | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $1.32B | Dec 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $35.20M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $36.10M | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $33.70M | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $34.70M | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $33.60M | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $31.90M | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $32.50M | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $33.80M | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $34.20M | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $34.70M | Dec 7, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $996.62M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $1.01B | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $942.17M | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $879.27M | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $853.07M | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $761.32M | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $727.58M | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $841.21M | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $759.30M | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $871.97M | Dec 7, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $845.25M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $1.27B | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $1.05B | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $1.13B | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $1.00B | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $1.13B | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $923.00M | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $1.24B | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $1.03B | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $1.04B | Dec 7, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $310.90M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $256.44M | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $270.21M | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $278.92M | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $232.42M | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $367.50M | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $293.84M | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $389.61M | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $221.29M | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $255.52M | Dec 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $13.39B | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $13.43B | Dec 5, 2025 |
| FY2024 | Oct 29, 2023 | $13.45B | Dec 5, 2024 |
| FY2023 | Oct 30, 2022 | $13.31B | Dec 6, 2023 |
| FY2022 | Oct 31, 2021 | $12.70B | Dec 6, 2022 |
| FY2021 | Oct 25, 2020 | $9.91B | Dec 10, 2021 |
| FY2021 | Oct 27, 2019 | $8.11B | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $8.14B | Dec 4, 2020 |
| FY2018 | Oct 29, 2017 | $6.98B | Dec 7, 2018 |
| FY2019 | Oct 30, 2016 | $6.98B | Dec 6, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $7.90B | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $7.99B | Dec 5, 2025 |
| FY2024 | Oct 29, 2023 | $7.73B | Dec 5, 2024 |
| FY2023 | Oct 30, 2022 | $7.54B | Dec 6, 2023 |
| FY2022 | Oct 31, 2021 | $6.97B | Dec 6, 2022 |
| FY2021 | Oct 25, 2020 | $6.43B | Dec 10, 2021 |
| FY2020 | Oct 27, 2019 | $5.92B | Dec 4, 2020 |
| FY2019 | Oct 28, 2018 | $5.60B | Dec 6, 2019 |
| FY2018 | Oct 29, 2017 | $4.94B | Dec 7, 2018 |
| FY2017 | Oct 30, 2016 | $4.45B | Dec 20, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $4.92B | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $4.92B | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $4.93B | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $4.93B | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $4.93B | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $2.61B | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $2.48B | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $2.71B | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $2.12B | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $1.83B | Dec 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $7.52B | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $7.68B | Dec 5, 2025 |
| FY2024 | Oct 29, 2023 | $7.49B | Dec 5, 2024 |
| FY2023 | Oct 30, 2022 | $7.31B | Dec 6, 2023 |
| FY2022 | Oct 31, 2021 | $6.88B | Dec 6, 2022 |
| FY2021 | Oct 25, 2020 | $6.52B | Dec 10, 2021 |
| FY2020 | Oct 27, 2019 | $6.13B | Dec 4, 2020 |
| FY2019 | Oct 28, 2018 | $5.73B | Dec 6, 2019 |
| FY2018 | Oct 29, 2017 | $5.16B | Dec 7, 2018 |
| FY2017 | Oct 30, 2016 | $4.74B | Dec 20, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $670.68M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $741.88M | Dec 5, 2025 |
| FY2024 | Oct 29, 2023 | $736.53M | Dec 5, 2024 |
| FY2023 | Oct 30, 2022 | $982.11M | Dec 6, 2023 |
| FY2022 | Oct 31, 2021 | $613.53M | Dec 6, 2022 |
| FY2021 | Oct 25, 2020 | $1.71B | Dec 10, 2021 |
| FY2020 | Oct 27, 2019 | $672.90M | Dec 4, 2020 |
| FY2019 | Oct 28, 2018 | $459.14M | Dec 6, 2019 |
| FY2018 | Oct 29, 2017 | $444.12M | Dec 7, 2018 |
| FY2018 | Oct 30, 2016 | $415.14M | Dec 7, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | 0 | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | 1 | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | 1 | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | 1 | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | 1 | Dec 6, 2023 |
| FY2020 | Oct 25, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Jul 26, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Apr 26, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Jan 26, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Oct 27, 2019 | 0 | Dec 4, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | 0 | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | 1 | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | 1 | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | 1 | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | 1 | Dec 6, 2023 |
| FY2020 | Oct 25, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Jul 26, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Apr 26, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Jan 26, 2020 | 0 | Dec 4, 2020 |
| FY2020 | Oct 27, 2019 | 0 | Dec 4, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 26, 2025 | $633.19M | Dec 5, 2025 |
| FY2025 | Oct 27, 2024 | $614.96M | Dec 5, 2025 |
| FY2025 | Oct 29, 2023 | $592.93M | Dec 5, 2025 |
| FY2024 | Oct 30, 2022 | $557.84M | Dec 5, 2024 |
| FY2023 | Oct 31, 2021 | $523.11M | Dec 6, 2023 |
| FY2022 | Oct 25, 2020 | $487.38M | Dec 6, 2022 |
| FY2021 | Oct 27, 2019 | $437.05M | Dec 10, 2021 |
| FY2020 | Oct 28, 2018 | $388.11M | Dec 4, 2020 |
| FY2019 | Oct 29, 2017 | $346.01M | Dec 6, 2019 |
| FY2018 | Oct 30, 2016 | $296.49M | Dec 7, 2018 |